Register for our free email digests:
Latest From Intrexon Corp.
Untapped market opportunities for treating and possibly curing underserved diseases have spurred an active deal-making environment in regenerative medicine, according to a new report from Datamonitor Healthcare.
Synthetic biology offers opportunity across many industries, but the ultimate prize may be health care. The millions of dollars investors have poured into companies developing CAR-T cell therapies and gene editing technologies points to growing confidence in the power of gene manipulation to generate novel, approvable therapeutics, even if for now these are just the early steps toward creating fully synthetic organisms.
Intrexon’s acquisitions since mid-2014 have given it a shot at solving some high-profile challenges, and have attracted mainstream pharmaceutical partners.
Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.
Drug Discovery Tools
- Molecular Diversity
- Synthesis Technologies, Production Processes
- Drug Discovery Tools
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- RheoGene Inc.
- Genomatix Ltd.
- North America
- Parent & Subsidiaries
- Intrexon Corp.
- Senior Management
Randal J Kirk, Chmn. & CEO
Rick Sterling, CFO
Thomas D Reed, PhD, CSO
Andrew J Last, COO
- Contact Info
Phone: (301) 556-9900
20358 Seneca Meadows Parkway
Germantown, MD 20876
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.